Orna rounds up $371M via series B, deal with Merck for circular RNAs

August 16, 2022 – A deal with Merck and a $221 million series B round will allow Orna’s lead circular RNA program to reach the clinic, while giving the pharma access to a platform to develop vaccines and therapeutics for infectious diseases and cancer.